Multibacillary leprosy is a type of leprosy that affects more than six skin spots. It's classified based on how many skin spots there are and if the bacteria are found in the skin. This type of leprosy needs more intensive treatment with antibiotics. It's a more severe form of the infection.
Every report comes from a Lived member, sent anonymously.
Have you tried Rifampin for Multibacillary Leprosy?
Leprosy, also called Hansen's disease, is a long-lasting bacterial infection of the skin and the nerves that run to the hands, feet and face. It can also affect the eyes and the lining of the nose. Its most serious effect is nerve damage: areas of skin can lose feeling, and muscles in the hands, feet or face can weaken. Leprosy is curable with antibiotics, and treating it early is the best way to prevent lasting disability. Multibacillary leprosy is the form in which the infection is more extensive in the body. The World Health Organization (WHO) groups leprosy into two treatment categories. A person has multibacillary disease if they have more than five skin patches, if a nerve is involved, or if the bacteria can be seen under a microscope in a sample scraped from the skin. In this form the immune system controls the bacteria poorly, so they multiply and spread more widely through the skin. It includes the types doctors call lepromatous, borderline lepromatous and midborderline leprosy, names that may appear on a biopsy or clinic report. The other category, paucibacillary leprosy, has a few patches, fewer bacteria and a shorter course of treatment.
Leprosy is caused by the bacterium Mycobacterium leprae, and rarely by a close relative, Mycobacterium lepromatosis. It is thought to spread through droplets from the nose and mouth of someone with untreated leprosy, usually after prolonged, close contact such as living in the same household. It does not spread through casual contact such as shaking hands, hugging, sharing a meal or sitting next to someone, and people stop spreading it once treatment begins. Most people are not susceptible: the US Centers for Disease Control and Prevention (CDC) estimates that about 95% of people's immune systems can fight off the bacteria. Whether an exposed person develops leprosy, and which form, depends largely on how their immune system responds. The bacteria grow very slowly, so signs can appear many years after exposure, sometimes up to 20. The main risk factor worldwide is having lived in a country where leprosy is still common, such as Brazil, India or Indonesia. In the United States the disease is rare, about 200 cases a year, and many are in people who acquired it abroad. Some wild nine-banded armadillos in the southern United States carry the bacteria, and contact with armadillos or the soil where they live is a possible source of locally acquired cases, though the risk to any one person is very low.
Leprosy is usually diagnosed by examining the skin and nerves. Clinicians look for three key signs: a pale or reddish skin patch with a definite loss of feeling, a thickened nerve with numbness or weakness in the area that nerve supplies, or bacteria seen in a skin sample. Testing feeling in a patch, for example with a light touch or a fine filament, is a central part of the exam. In multibacillary leprosy the patches can be numerous, faint and poorly outlined, and feeling may be preserved early on, which is one reason it can be missed. The diagnosis is usually confirmed with a skin biopsy or a slit-skin smear, in which a small amount of fluid is scraped from a tiny cut and stained to look for the bacteria. Laboratory tests that detect the bacteria's genetic material (polymerase chain reaction, or PCR) can add confirmation. These results also decide the treatment category: finding bacteria in the skin makes a case multibacillary however few patches there are. Because leprosy is uncommon in the United States, it is often mistaken at first for other skin conditions, and a dermatologist or infectious disease specialist familiar with it may be involved.
Multibacillary leprosy is cured with a combination of antibiotics taken for a long time, because the bacteria grow slowly and a single drug would allow resistance to develop. In most of the world the standard is the WHO regimen, called multidrug therapy, which combines three medicines: rifampicin (called rifampin in the US), dapsone and clofazimine, taken as a mix of daily and once-monthly doses for 12 months. In the United States, care is usually guided by the National Hansen's Disease Program, a federal program that advises clinicians and patients. It now generally recommends a different combination taken once a month for about 24 months: rifampin, moxifloxacin (a fluoroquinolone antibiotic) and minocycline (a tetracycline antibiotic). Its older approach used the three WHO drugs daily for 24 months. Studies suggest the monthly combination works as well with fewer side effects and far fewer pills, but this evidence comes from smaller studies, so the regimen depends on the specialist's advice and the person's other health conditions. Each drug has trade-offs worth knowing. Clofazimine commonly darkens the skin, especially on the face and limbs; the change fades after treatment ends but can take a long time to do so. Rifampin, on either schedule, can turn urine, sweat and tears orange or red and can make many other medicines less effective, including hormonal birth control (so another method may be needed) and blood thinners, so the prescriber needs a full medication list. Dapsone can cause allergic skin reactions and anemia from a breakdown of red blood cells, so a blood test for G6PD (glucose-6-phosphate dehydrogenase) deficiency, an inherited condition that raises this risk, is usually done before it is started, and blood counts are monitored. Treatment also has to manage leprosy reactions. These are flare-ups of the immune system against the bacteria, and they can happen before, during or after antibiotic treatment. In multibacillary leprosy, a common type is erythema nodosum leprosum (ENL): crops of painful red lumps under the skin, often with fever, joint pain, swollen nerves or eye inflammation. Another type inflames existing patches and nerves. Reactions are treated with anti-inflammatory medicines, most often corticosteroid (steroid) pills tapered over several months. Severe ENL may be treated with thalidomide (Thalomid), which works quickly but causes severe birth defects, so it is never used in pregnancy and is prescribed only through a restricted program. Antibiotics are continued during a reaction. Where nerves are already damaged, physical and occupational therapy, protective footwear, splints and sometimes surgery help preserve function.
Antibiotic treatment cures the infection, and people stop being contagious once it starts. People with leprosy can keep working, going to school and living at home with their families. Treatment is long, though, and completing it as prescribed matters, because stopping early risks relapse and drug resistance. Skin patches fade slowly, often over months to years after the bacteria are killed. The largest ongoing issue is the nerves. Feeling or strength already lost may not come back, and reactions can cause new nerve damage even after the bacteria are gone, sometimes years later. This is why follow-up continues during and after treatment, with regular checks of feeling and strength in the hands, feet and eyes. Loss of feeling means burns, cuts, blisters and pressure sores can go unnoticed and become infected, so a daily routine of checking and protecting numb hands and feet, wearing well-fitting shoes, and protecting the eyes if blinking is weak is a lasting part of life for many people. Leprosy still carries stigma in many communities, and worries about how others will react can weigh as heavily as the physical effects. Knowing that the disease is curable and is not spread by everyday contact can help in deciding whom to tell.
See a clinician if you have a skin patch that has lost feeling, or persistent numbness or weakness in the hands or feet, especially if you have lived in a country where leprosy is common or have had close contact with someone who had it. If you have been diagnosed, contact your care team promptly about signs of a reaction: new painful red lumps under the skin, fever, skin patches that suddenly become red and swollen, nerves that become painful or tender, or new numbness or weakness in the hands, feet or face. Starting treatment for a reaction early protects the nerves. A painful red eye or blurred vision needs to be checked the same day.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Multibacillary Leprosy is like, what's helped you, or ask the community a question.